First 18F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts
- 1 July 2013
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 40 (5) , 618-624
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Quantitative PET of Human Urokinase-Type Plasminogen Activator Receptor with 64Cu-DOTA-AE105: Implications for Visualizing Cancer InvasionJournal of Nuclear Medicine, 2012
- Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian CancerJournal of Nuclear Medicine, 2011
- Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging ProbesCurrent Drug Targets, 2011
- The radiolabeling of proteins by the [18F]AlF methodApplied Radiation and Isotopes, 2011
- High-Yielding Aqueous 18F-Labeling of Peptides via Al18F ChelationBioconjugate Chemistry, 2011
- One-step radiosynthesis of 18F-AlF-NOTA-RGD2 for tumor angiogenesis PET imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Tumor markers in prostate cancer I: Blood-based markersActa Oncologica, 2011
- An Anti-Urokinase Plasminogen Activator Receptor Antibody (ATN-658) Blocks Prostate Cancer Invasion, Migration, Growth, and Experimental Skeletal Metastasis In Vitro and In VivoNeoplasia, 2010
- A Novel Facile Method of Labeling Octreotide with 18F-FluorineJournal of Nuclear Medicine, 2010
- Other biomarkers for detecting prostate cancerBJU International, 2010